Gene Therapy Licensing Pharma Companies Regulation 
pharmaphorum
DECEMBER 22, 2021
Gyroscope Therapeutics and its gene therapy for the sight-robbing disease geographic atrophy (GA) has been acquired by a big pharma company – but likely not the one you would expect. CFI regulates the activity of the complement immune system which is over-activated in GA. It has been fast-tracked by the FDA.
XTalks
DECEMBER 29, 2022
For example, on the pharma and biotech side, there has been growing demand for new drugs and biologics, from new classes of dual-action diabetes and weight loss drugs like Ozempic and Mounjaro to life-saving gene therapies. 1. Cell and Gene Therapies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
MAY 6, 2024
A more established Amsterdam-based enterprise is gene therapy company uniQure, developer of etranacogene dezaparvovec, the first gene therapy for haemophilia B, which was approved for use in the US in November 2022 and in the EU in February 2023.
pharmaphorum
NOVEMBER 30, 2022
The biggest gathering of pharma companies in Europe right now on the commercial side, the Veeva Systems Summit permits the sharing of best practices and of new ideas. Facts that they gleaned included: Across Europe, only 52% of HCPs will accept a visit from a pharma company (i.e. Veeva is equally ‘super excited’.
Drug Discovery World
MARCH 29, 2023
The commission is looking to put more pressure on pharma companies to report such shortages, and to offer a drug’s marketing authorisation to another company before withdrawing it from the market. She also does not believe that the problems with Europe’s medicines can be solved with regulation.
pharmaphorum
SEPTEMBER 1, 2020
.” This public-spirited industry still required greater oversight, however, and government regulations on medicines increased on both sides of the Atlantic. Thalidomide and the development of drug safety regulation and monitoring. George Merck on the cover of Time magazine.
XTalks
MARCH 22, 2023
While not a record-breaking deal at $17 billion, the buyout strengthened Pfizer’s injectables business unit with the company reporting an 11 percent increase in revenue the following year. And drugmakers are using their R&D expenditure to justify setting astronomically high list prices for new therapies.
Expert insights. Personalized for you.
102 
Let's personalize your content